Jump Financial LLC Takes $64,000 Position in Savara Inc (NASDAQ:SVRA)

Jump Financial LLC acquired a new stake in Savara Inc (NASDAQ:SVRA) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 20,755 shares of the company’s stock, valued at approximately $64,000.

A number of other hedge funds also recently made changes to their positions in the business. China Universal Asset Management Co. Ltd. lifted its position in shares of Savara by 14.9% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 36,390 shares of the company’s stock valued at $112,000 after buying an additional 4,732 shares during the last quarter. Barclays PLC lifted its position in shares of Savara by 2.5% in the fourth quarter. Barclays PLC now owns 236,705 shares of the company’s stock valued at $728,000 after buying an additional 5,700 shares during the last quarter. SG Americas Securities LLC lifted its holdings in Savara by 14.0% during the 4th quarter. SG Americas Securities LLC now owns 51,589 shares of the company’s stock worth $158,000 after purchasing an additional 6,330 shares during the last quarter. Rhumbline Advisers lifted its holdings in Savara by 6.8% during the 4th quarter. Rhumbline Advisers now owns 141,425 shares of the company’s stock worth $434,000 after purchasing an additional 9,041 shares during the last quarter. Finally, Cibc World Markets Corp acquired a new stake in Savara during the 4th quarter worth approximately $33,000. 87.93% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reissued a “buy” rating and set a $6.00 price target on shares of Savara in a report on Friday, March 28th. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $8.83.

Savara Price Performance

Shares of NASDAQ SVRA opened at $3.19 on Tuesday. The stock has a market capitalization of $550.70 million, a PE ratio of -7.42 and a beta of 0.52. The company has a debt-to-equity ratio of 0.13, a current ratio of 17.70 and a quick ratio of 17.70. The business has a fifty day moving average price of $2.78 and a two-hundred day moving average price of $3.06. Savara Inc has a fifty-two week low of $2.26 and a fifty-two week high of $5.31.

Savara (NASDAQ:SVRA) last posted its earnings results on Thursday, March 27th. The company reported ($0.13) EPS for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.02). The firm had revenue of $0.27 million for the quarter. As a group, equities analysts predict that Savara Inc will post -0.45 earnings per share for the current fiscal year.

Savara Profile

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.